{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:33:23Z","timestamp":1792168403285,"version":"4.4.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014857","name":"National Natural Science Foundation of China-Guangdong Joint Fund","doi-asserted-by":"publisher","award":["81800356"],"award-info":[{"award-number":["81800356"]}],"id":[{"id":"10.13039\/501100014857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bcp.2022.115162","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T19:42:36Z","timestamp":1656877356000},"page":"115162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["JAK inhibition as a new treatment strategy for patients with COVID-19"],"prefix":"10.1016","volume":"202","author":[{"given":"Jin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinniu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.bcp.2022.115162_b0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bcp.2022.115162_b0010","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2022.115162_b0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"10229","key":"10.1016\/j.bcp.2022.115162_b0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.bcp.2022.115162_b0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0030","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200674","article-title":"Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies","volume":"217","author":"Zhou","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2022.115162_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","volume":"88","author":"Owji","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK Inhibition as a New Treatment Strategy for Patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int Arch Allergy Immunol."},{"issue":"16","key":"10.1016\/j.bcp.2022.115162_b0045","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"10224","key":"10.1016\/j.bcp.2022.115162_b0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0065","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2022.115162_b0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","article-title":"Why tocilizumab could be an effective treatment for severe COVID-19?","volume":"18","author":"Fu","year":"2020","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad. Med."},{"issue":"10229","key":"10.1016\/j.bcp.2022.115162_b0090","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"Hlh Across Speciality Collaboration UK: COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0095","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases?","volume":"20","author":"Schett","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0105","doi-asserted-by":"crossref","first-page":"e00165","DOI":"10.1128\/mBio.00165-13","article-title":"Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus","volume":"4","author":"Josset","year":"2013","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0110","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.4049\/jimmunol.1100917","article-title":"IL-17 boosts proinflammatory outcome of antiviral response in human cells","volume":"187","author":"Ryzhakov","year":"2011","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.bcp.2022.115162_b0115","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2022.115162_b0120","doi-asserted-by":"crossref","first-page":"118167","DOI":"10.1016\/j.lfs.2020.118167","article-title":"The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis","volume":"258","author":"Akbari","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2022.115162_b0130","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 Cytokine Storm; What We Know So Far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2022.115162_b0135","doi-asserted-by":"crossref","first-page":"588654","DOI":"10.3389\/fphar.2020.588654","article-title":"Challenges for Drug Repurposing in the COVID-19 Pandemic Era","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1120009X.2020.1868237","article-title":"Therapeutic options for COVID-19: a quick review","volume":"33","author":"Ismaila","year":"2021","journal-title":"J. Chemother."},{"key":"10.1016\/j.bcp.2022.115162_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbi.2020.04.046","article-title":"Current status of potential therapeutic candidates for the COVID-19 crisis","volume":"87","author":"Zhang","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin. Immunopathol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0160","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"13","key":"10.1016\/j.bcp.2022.115162_b0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.9.13.7557015","article-title":"How do protein kinases discriminate between serine\/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase","volume":"9","author":"Taylor","year":"1995","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0170","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.tips.2019.03.001","article-title":"Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease","volume":"40","author":"Durham","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"49","key":"10.1016\/j.bcp.2022.115162_b0180","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"issue":"Supplement_2","key":"10.1016\/j.bcp.2022.115162_b0185","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1093\/ecco-jcc\/jjz206","article-title":"Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors","volume":"14","author":"Garrido-Trigo","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0190","first-page":"1347","article-title":"JAK2, a third member of the JAK family of protein tyrosine kinases","volume":"7","author":"Harpur","year":"1992","journal-title":"Oncogene"},{"issue":"28","key":"10.1016\/j.bcp.2022.115162_b0195","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6485","key":"10.1016\/j.bcp.2022.115162_b0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/370151a0","article-title":"Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2","volume":"370","author":"Johnston","year":"1994","journal-title":"Nature"},{"issue":"6485","key":"10.1016\/j.bcp.2022.115162_b0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/370153a0","article-title":"Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells","volume":"370","author":"Witthuhn","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115162_b0210","doi-asserted-by":"crossref","first-page":"7492904","DOI":"10.1155\/2018\/7492904","article-title":"Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?","volume":"2018","author":"Kotyla","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0215","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.4049\/jimmunol.1700842","article-title":"Cytokine-Mediated Regulation of Human Lymphocyte Development and Function: Insights from Primary Immunodeficiencies","volume":"199","author":"Tangye","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2022.115162_b0220","doi-asserted-by":"crossref","unstructured":"A.V. Villarino, M. Gadina, J.J. O'Shea, Y. Kanno, SnapShot: Jak-STAT Signaling II, Cell 181(7) (2020) 1696-1696 e1691.","DOI":"10.1016\/j.cell.2020.04.052"},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0225","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0235","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0240","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2022.115162_b0245","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0250","doi-asserted-by":"crossref","first-page":"998","DOI":"10.4049\/jimmunol.180.2.998","article-title":"Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation","volume":"180","author":"Haan","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0255","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2","volume":"21","author":"Wallweber","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0265","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2174\/0929867325666180327093502","article-title":"An Update on JAK Inhibitors","volume":"26","author":"Musumeci","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0270","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbamcr.2007.01.002","article-title":"Regulation of MAPKs by growth factors and receptor tyrosine kinases","volume":"1773","author":"Katz","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"34","key":"10.1016\/j.bcp.2022.115162_b0275","doi-asserted-by":"crossref","first-page":"14157","DOI":"10.1073\/pnas.1107747108","article-title":"Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains","volume":"108","author":"Lee","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2022.115162_b0280","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J. Autoimmun."},{"issue":"5237","key":"10.1016\/j.bcp.2022.115162_b0285","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bcp.2022.115162_b0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","article-title":"The potential and controversy of targeting STAT family members in cancer","volume":"60","author":"Verhoeven","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0295","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cell.2007.10.033","article-title":"SnapShot: JAK-STAT signaling","volume":"131","author":"Mertens","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0300","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2022.115162_b0305","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0315","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"issue":"5237","key":"10.1016\/j.bcp.2022.115162_b0320","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"issue":"5237","key":"10.1016\/j.bcp.2022.115162_b0325","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.270.5237.794","article-title":"Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3","volume":"270","author":"Thomis","year":"1995","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0335","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.115162_b0340","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","volume":"86","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2022.115162_b0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","article-title":"How COVID-19 induces cytokine storm with high mortality","volume":"40","author":"Hojyo","year":"2020","journal-title":"Inflamm. Regen."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0350","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002838","article-title":"JAK inhibitors and COVID-19","volume":"10","author":"Levy","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0355","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2020.1780120","article-title":"JAK selectivity: more precision less troubles","volume":"14","author":"Roda","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0360","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0365","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/sj.bjc.6604285","article-title":"Gene expression reveals two distinct groups of anal carcinomas with clinical implications","volume":"98","author":"Bruland","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0370","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cei.12970","article-title":"Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production","volume":"189","author":"Mitchell","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0375","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/kex426","article-title":"Targeted inhibition of Janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes","volume":"57","author":"Karonitsch","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2022.115162_b0380","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System","volume":"9","author":"Kubo","year":"2018","journal-title":"Front. Immunol."},{"issue":"10223","key":"10.1016\/j.bcp.2022.115162_b0385","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0390","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.str.2015.12.015","article-title":"Family-wide Structural Analysis of Human Numb-Associated Protein Kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0395","doi-asserted-by":"crossref","first-page":"14159","DOI":"10.1038\/s41598-019-50335-5","article-title":"Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells","volume":"9","author":"Eberl","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0400","doi-asserted-by":"crossref","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0405","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0410","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0415","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0420","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0425","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.bcp.2022.115162_b0430","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bcp.2022.115162_b0435","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0440","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0445","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol."},{"issue":"23","key":"10.1016\/j.bcp.2022.115162_b0450","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Saif Ur Rehman S, Shirai CL, Vij K, DiPersio JF: Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2022.115162_b0455","doi-asserted-by":"crossref","first-page":"112087","DOI":"10.1016\/j.fct.2021.112087","article-title":"Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review","volume":"150","author":"Smail","year":"2021","journal-title":"Food Chem. Toxicol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0460","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0465","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.218","article-title":"A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers","volume":"54","author":"Zhang","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0470","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/13543784.2013.811231","article-title":"Tofacitinib in kidney transplantation","volume":"22","author":"Wojciechowski","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2022.115162_b0475","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0480","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0485","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrrheum.2015.140","article-title":"Vitamin D in rheumatoid arthritis-towards clinical application","volume":"12","author":"Jeffery","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0490","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13054-020-03020-3","article-title":"Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients","volume":"24","author":"Convertino","year":"2020","journal-title":"Crit Care"},{"issue":"24","key":"10.1016\/j.bcp.2022.115162_b0495","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0500","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"CD013881","key":"10.1016\/j.bcp.2022.115162_b0505","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","volume":"3","author":"Ghosn","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0510","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000509483","article-title":"Weathering the Cytokine Storm in COVID-19: Therapeutic Implications","volume":"10","author":"Iannaccone","year":"2020","journal-title":"Cardiorenal. Med."},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0515","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0520","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0525","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"Bronte","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0530","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0535","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0540","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2022.115162_b0545","unstructured":"P.W. Horby, J.R. Emberson, M. Mafham, M. Campbell, L. Peto, G. Pessoa-Amorim, E. Spata, N. Staplin, C. Lowe, D.R. Chadwick et al: 2022."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0550","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/med-2021-0010","article-title":"Additional baricitinib loading dose improves clinical outcome in COVID-19","volume":"16","author":"Hasan","year":"2021","journal-title":"Open Med. (Wars)"},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0555","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s13063-020-04535-4","article-title":"Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Kulkarni","year":"2020","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.bcp.2022.115162_b0560","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0565","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0570","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Rosee","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0575","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0580","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41375-020-0907-9","article-title":"Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)","volume":"34","author":"Neubauer","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0585","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"issue":"466","key":"10.1016\/j.bcp.2022.115162_b0590","article-title":"Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol","volume":"7","author":"Capochiani","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0595","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/cts.12971","article-title":"Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation","volume":"14","author":"Mortara","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0600","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41375-021-01374-3","article-title":"The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)","volume":"35","author":"Neubauer","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2022.115162_b0605","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0610","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia","volume":"385","author":"Guimaraes","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0615","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2021","article-title":"A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19","volume":"58","author":"Singh","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.bcp.2022.115162_b0620","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jcph.1874","article-title":"Baricitinib: From Rheumatoid Arthritis to COVID-19","volume":"61","author":"Assadiasl","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0625","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s13054-020-03098-9","article-title":"Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China","volume":"24","author":"Xu","year":"2020","journal-title":"Crit. Care"},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0630","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","article-title":"Baricitinib for COVID-19: a suitable treatment?","volume":"20","author":"Favalli","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0635","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"Cameron","year":"2008","journal-title":"Virus Res."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0640","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.bcp.2022.115162_b0645","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0650","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0655","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bcp.2022.115162_b0660","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0665","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0670","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01919-2020","article-title":"JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk","volume":"56","author":"Mehta","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0675","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0680","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul. Fibrinol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0685","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0690","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2022.115162_b0695","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0700","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.120687","article-title":"Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure","volume":"40","author":"Genovese","year":"2013","journal-title":"J. Rheumatol."},{"issue":"23","key":"10.1016\/j.bcp.2022.115162_b0705","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0710","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jth.14830","article-title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia","volume":"18","author":"Cui","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"23","key":"10.1016\/j.bcp.2022.115162_b0715","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115162_b0720","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S2352-3026(20)30109-5","article-title":"Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19","volume":"7","author":"Wang","year":"2020","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0725","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2022.115162_b0730","doi-asserted-by":"crossref","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"218","author":"Yeleswaram","year":"2020","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2022.115162_b0735","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0740","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0745","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12967-020-02573-9","article-title":"Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial","volume":"18","author":"Perrone","year":"2020","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0750","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/leu.2015.218","article-title":"Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function","volume":"30","author":"Perner","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2022.115162_b0755","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/ajh.25985","article-title":"Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19","volume":"95","author":"Wilcox","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115162_b0760","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.bcp.2022.115162_b0765","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2022.115162_b0770","doi-asserted-by":"crossref","unstructured":"A living WHO guideline on drugs for covid-19, BMJ 377 (2022) o1045.","DOI":"10.1136\/bmj.o1045"},{"issue":"10225","key":"10.1016\/j.bcp.2022.115162_b0775","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2022.115162_b0780","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0785","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"10223","key":"10.1016\/j.bcp.2022.115162_b0790","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0795","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jinf.2020.03.022","article-title":"The index case of SARS-CoV-2 in Scotland","volume":"81","author":"Hill","year":"2020","journal-title":"J. Infect."},{"issue":"13","key":"10.1016\/j.bcp.2022.115162_b0800","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis","volume":"324","author":"Group WHOREAfC-TW","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.bcp.2022.115162_b0805","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.bcp.2022.115162_b0810","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2022.115162_b0815","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2022.115162_b0820","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.bcp.2022.115162_b0825","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bcp.2022.115162_b0830","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001899","article-title":"Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider","volume":"7","author":"Alunno","year":"2021","journal-title":"RMD Open"},{"issue":"16","key":"10.1016\/j.bcp.2022.115162_b0835","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10285","key":"10.1016\/j.bcp.2022.115162_b0840","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0845","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis","volume":"326","author":"Group WHOREAfC-TW","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0850","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12916-017-0930-5","article-title":"Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis","volume":"15","author":"Kyriazopoulou","year":"2017","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0855","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/nsr\/nwaa037","article-title":"Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury","volume":"7","author":"Liu","year":"2020","journal-title":"Natl. Sci. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2022.115162_b0860","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Xing L et al.: Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115162_b0865","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.bcp.2022.115162_b0870","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1378\/chest.08-1116","article-title":"Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria","volume":"134","author":"Kollef","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.bcp.2022.115162_b0875","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","article-title":"A Case Series on Patients on Tofacitinib in Combination With a Biologic","volume":"24","author":"Barroso","year":"2018","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2022.115162_b0880","article-title":"Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study","author":"Rosas","year":"2020","journal-title":"Reumatol. Clin. (Engl. Ed.)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222002568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222002568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:39:34Z","timestamp":1757770774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222002568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":176,"alternative-id":["S0006295222002568"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115162","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibition as a new treatment strategy for patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115162"}}